104 |
Serum Glucocorticoid-inducible Kinase-1( SGK1) Levels in Patients with Psoriatic Arthritis |
105 |
Differential NH2-terminal autoantigen trimming may explain epistasis between HLA-C * 06:02 and ERAP1 variants in psoriasis risk |
106 |
Environmental triggers of an HLA-C * 06:02-restricted autoimmune response in psoriasis |
107 |
A skewed pool of resident T cells triggers disease-associated tissue responses in never- lesional psoriasis |
Psoriasis and Psoriatic Arthritis relationship | |
108 |
Nail involvement in psoriasis; is it a predictor of psoriatic arthritis? |
109 |
Absolute and relative PASI improvements with ixekizumab treatment: Results at Week 12 from IXORA-P |
110 |
Prevalence and sex differences of psoriatic arthritis in patients with severe plaque psoriasis. |
111 |
Skin Lesion Severity In Early Axial and Peripheral Psoriatic Arthritis Patients |
112 |
Gastrointestinal symptoms are common in U. S. patients with moderate-severe psoriasis |
113 |
Secukinumab’ s Long-Term Safety Remains Favorable up to 5 Years of Treatment |
114 |
Impact of Improvement in Skin and Joint on Quality of Life in Active Psoriatic Arthritis Patients |
115 |
Secukinumab Shows High and Sustained Efficacy in Subjects with Moderate to Severe Palmoplantar Psoriasis: 2.5-Year Results From the |
GESTURE Study | |
116 |
Secukinumab Shows High and Sustained Efficacy in Nail Psoriasis: 2.5-Year TRANSFIGURE Study Results |
117 |
The obesity and prevalence psoriatic arthritis in patients with plaque psoriasis: dermatological real-setting data. |
118 |
Diagnosis of Psoriatic Arthritis in Patients with Moderate to Severe Chronic Plaque Psoriasis Treated with Secukinumab vs. Other Treatments |
in the PURE Registry: Indication of Selection Preferences and Underdiagnosis | |
119 |
Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks |
120 |
Tildrakizumab efficacy over time by week 28 response levels in two Phase 3 clinical trials in patients with chronic plaque psoriasis |
122 |
Potential Disconnect: Co-Management of Patients with Psoriatic Arthritis Between Rheumatologists and Dermatologists |
123 |
The Use of Tumor Necrosis Factor Inhibitors( TNF) in the Second-Line Biologic / Small Molecule Setting: A Cross-Specialty Comparison |
124 |
Impact of Guselkumab versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in |
VOYAGE 2 | |
Quality of Life | |
125 |
The Dermatology Life Quality Index in Russian patients with psoriasis and psoriatic arthritis. |
126 |
Effects of mindfulness-based cognitive therapy on self-reported psoriasis and psychological symptoms |
127 |
A mixed methods study exploring the impact of mindfulness on psoriasis, anxiety, depression and QoL |
128 |
A link between quality of patient-physician communication and patient healthcare needs in PsA |
129 |
Psoriasis Patients Point of View: What bare we Missing when Managing Them? |
130 |
The impact of psoriasis and psoriatic arthritis on quality of life and career in Scandinavia |
131 |
Quality of life of patients with psoriasis in Khartoum dermatology hospital, December 2017 |
132 |
Mirikizumab Significantly Improves Self-Reported Disease Severity and General Health Status in Patients with Moderate-to-Severe Psoriasis |
133 |
Effect of Tildrakizumab on Personal Relationships in Patients with Moderate-to-Severe Chronic Plaque Psoriasis |
134 |
Pruritus severity assessment and correlation with baseline characteristics of patients with psoriasis vulgaris: an exploratory analysis of the |
Phase IIIb, PSORITUS study | |
135 |
Quality of life and psychosocial implications in patients with psoriasis |
136 |
Swedish psoriatic patients’ perspective of their disease. Results from an observational patient survey. |
137 |
Ixekizumab Provides Greater Cumulative Benefits versus Ustekinumab over 24 Weeks for Patients with Moderate-to-Severe Psoriasis in |
a Randomized, Double-Blind Phase 3b Clinical Trial | |
138 |
Coach @ Home: A Support Program for Patients Treated With Certolizumab Pegol |
139 |
A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis |
140 |
The Psychosocial Impact of Psoriasis: Differential Experiences of Men and Women in Early Adulthood |
141 |
Certolizumab Pegol Improves Patient-Reported Outcomes in Chronic Plaque Psoriasis Over 1 Year |
142 |
Translating WHO resolution into the public: the German program against stigmatization of people with chronic visible skin diseases |
143 |
The Global Research on the Impact of Dermatological Diseases( GRIDD) |
Young scientists( born on or after January 1, 1983) | |
144 |
Treatment of Nail Psoriasis with Different Pulse Durations of Pulsed Dye Laser |
145 |
Neutropenia in a psoriasis patient: Secukinumab or micronutrient deficiency? |
146 |
Establishment of a Psoriatic Skin Model for α-Irradiation |
147 |
The History of Psoriasis |
148 |
Comorbidities and treatments in patients with inverse psoriasis |
Late Breakers | |
150 |
Development of the“ PsO Sleepy-Q” and the“ PsA Sleepy-Q”: two questionnaires to characterize sleep in patients with psoriatic disease |
151 |
Unstable forms of psoriasis – indicator of an intermediate state of systemic disease |
152 |
Could biological agents foster suicide through its potential antidepressant mechanism? A Psychodermatological approach. |
153 |
Treating the pain, not the problem? Results from a Swedish online survey on psoriatic arthritis and psoriasis with joint pain. |
154 |
An International Delphi survey to define screening for psoriatic arthritis and measurement of psoriatic arthritis symptoms in psoriasis |
clinical trials | |
155 |
The impact of a diagnosis on the patients’ perception of treatment and care. Results from an online survey on psoriatic arthritis and psoriasis |
with joint pain. | |